Pax Margaret
CIK: 0001999772
Pax Margaret's purchase track record
Pax Margaret has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/17/2025 | RGEN | $38K | -17.5% | -25.6% | +16.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| RGEN | ▲ Buy | Grant | 995 | $0 | 5/14/2026 | View on chart |
| RGEN | ▲ Buy | Grant | 973 | $0 | 5/15/2025 | View on chart |
| RGEN | ▲ Buy | Open Market | 250 | $38K | 3/17/2025 | View on chart |
| RGEN | ▲ Buy | Grant | 701 | $0 | 5/16/2024 | View on chart |
| RGEN | ▲ Buy | Grant | 92 | $0 | 3/18/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Repligen Completes BioLife Solutions Acquisition
Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.
Repligen Completes BioLife Solutions Acquisition. Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.